公开(公告)号：US20240408166A1

公开(公告)日：2024-12-12

申请号：US18814073

申请日：2024-08-23

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K38/04 ,  A61K35/12 ,  A61K35/17 ,  A61K39/00 ,  A61K51/10 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20220054613A1

公开(公告)日：2022-02-24

申请号：US17508295

申请日：2021-10-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/00 ,  A61K38/04 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  A61K35/17 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20220257739A1

公开(公告)日：2022-08-18

申请号：US17728756

申请日：2022-04-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/00 ,  C07K7/08 ,  A61K51/10 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20220023403A1

公开(公告)日：2022-01-27

申请号：US17502170

申请日：2021-10-15

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/00 ,  A61K38/04 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  A61K35/17 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20220354939A1

公开(公告)日：2022-11-10

申请号：US17852623

申请日：2022-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K35/17 ,  G01N33/68 ,  C07K14/74 ,  C07K14/435 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/725 ,  A61K51/10 ,  A61K38/04 ,  C07K7/00 ,  C07K7/08 ,  C07K16/18 ,  C07K7/06

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20220031824A1

公开(公告)日：2022-02-03

申请号：US17508230

申请日：2021-10-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/00 ,  A61K38/04 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74 ,  A61K35/17 ,  C07K7/06

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20210268089A1

公开(公告)日：2021-09-02

申请号：US17245918

申请日：2021-04-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/00 ,  C07K7/08 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20220339272A1

公开(公告)日：2022-10-27

申请号：US17853344

申请日：2022-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K35/17 ,  G01N33/68 ,  C07K14/74 ,  C07K14/435 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/725 ,  A61K51/10 ,  A61K38/04 ,  C07K7/00 ,  C07K7/08 ,  C07K16/18 ,  C07K7/06

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20220118071A1

公开(公告)日：2022-04-21

申请号：US17516304

申请日：2021-11-01

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  A61K38/04 ,  C07K7/06 ,  C07K7/00 ,  C07K7/08 ,  A61K51/10 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  G01N33/68 ,  C07K14/435 ,  C07K14/725 ,  C07K14/74

Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.

公开(公告)号：US20180207252A1

公开(公告)日：2018-07-26

申请号：US15917098

申请日：2018-03-09

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MUELLER ,  Anita WIEBE ,  Sarah KUTSCHER

IPC: A61K39/00 ,  G01N33/68 ,  C07K14/725 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  A61K35/17 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K14/74 ,  A61K35/12

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/04 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C07K2317/70 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/998 ,  G01N33/6803

Abstract: A method of treating a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.